These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32459399)

  • 1. Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1.
    Armstrong AE; Rhodes SD; Smith A; Chen S; Bessler W; Ferguson MJ; Jiang L; Li X; Yuan J; Yang X; Yang FC; Robertson KA; Ingram DA; Blakeley JO; Clapp DW
    Pediatr Blood Cancer; 2020 Aug; 67(8):e28372. PubMed ID: 32459399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model.
    Demestre M; Herzberg J; Holtkamp N; Hagel C; Reuss D; Friedrich RE; Kluwe L; Von Deimling A; Mautner VF; Kurtz A
    J Neurooncol; 2010 May; 98(1):11-9. PubMed ID: 19921098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas.
    Ferguson MJ; Rhodes SD; Jiang L; Li X; Yuan J; Yang X; Zhang S; Vakili ST; Territo P; Hutchins G; Yang FC; Ingram DA; Clapp DW; Chen S
    Pediatr Blood Cancer; 2016 Feb; 63(2):206-13. PubMed ID: 26375012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.
    Robertson KA; Nalepa G; Yang FC; Bowers DC; Ho CY; Hutchins GD; Croop JM; Vik TA; Denne SC; Parada LF; Hingtgen CM; Walsh LE; Yu M; Pradhan KR; Edwards-Brown MK; Cohen MD; Fletcher JW; Travers JB; Staser KW; Lee MW; Sherman MR; Davis CJ; Miller LC; Ingram DA; Clapp DW
    Lancet Oncol; 2012 Dec; 13(12):1218-24. PubMed ID: 23099009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.
    Flint AC; Mitchell DK; Angus SP; Smith AE; Bessler W; Jiang L; Mang H; Li X; Lu Q; Rodriguez B; Sandusky GE; Masters AR; Zhang C; Dang P; Koenig J; Johnson GL; Shen W; Liu J; Aggarwal A; Donoho GP; Willard MD; Bhagwat SV; Clapp DW; Rhodes SD
    Clin Cancer Res; 2023 Sep; 29(17):3438-3456. PubMed ID: 37406085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 1.
    Mund JA; Park S; Smith AE; He Y; Jiang L; Hawley E; Roberson MJ; Mitchell DK; Abu-Sultanah M; Yuan J; Bessler WK; Sandusky G; Chen S; Zhang C; Rhodes SD; Clapp DW
    J Biol Chem; 2020 Jul; 295(29):9948-9958. PubMed ID: 32471868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of
    Burks CA; Rhodes SD; Bessler WK; Chen S; Smith A; Gehlhausen JR; Hawley ET; Jiang L; Li X; Yuan J; Lu Q; Jacobsen M; Sandusky GE; Jones DR; Clapp DW; Blakeley JO
    Mol Cancer Ther; 2019 Dec; 18(12):2321-2330. PubMed ID: 31527226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.
    Staser K; Yang FC; Clapp DW
    Annu Rev Pathol; 2012; 7():469-95. PubMed ID: 22077553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of pregnancy on growth-dynamics of neurofibromas in Neurofibromatosis type 1.
    Well L; Jaeger A; Kehrer-Sawatzki H; Farschtschi S; Avanesov M; Sauer M; de Sousa MT; Bannas P; Derlin T; Adam G; Mautner VF; Salamon JM
    PLoS One; 2020; 15(4):e0232031. PubMed ID: 32343738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased nuclear translation of YAP might act as a potential therapeutic target for NF1-related plexiform neurofibroma.
    Liu JL; You YH; Tian ZW; Xiao M; Zheng JW; Wang YA; Du Z
    Int J Med Sci; 2021; 18(9):2008-2016. PubMed ID: 33850471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation.
    Yu Y; Choi K; Wu J; Andreassen PR; Dexheimer PJ; Keddache M; Brems H; Spinner RJ; Cancelas JA; Martin LJ; Wallace MR; Legius E; Vogel KS; Ratner N
    Acta Neuropathol; 2020 Jan; 139(1):157-174. PubMed ID: 31664505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1.
    Mautner VF; Hartmann M; Kluwe L; Friedrich RE; Fünsterer C
    Neuroradiology; 2006 Mar; 48(3):160-5. PubMed ID: 16432718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions.
    Mußotter T; Kluwe L; Högel J; Nguyen R; Cooper DN; Mautner VF; Kehrer-Sawatzki H
    BMC Med Genet; 2012 Oct; 13():98. PubMed ID: 23101500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-Year Follow-up of Internal Neurofibroma Growth Behavior in Adult Patients With Neurofibromatosis Type 1 Using Whole-Body MRI.
    Ly KI; Merker VL; Cai W; Bredella MA; Muzikansky A; Thalheimer RD; Da JL; Orr CC; Herr HP; Morris ME; Chang CY; Harris GJ; Plotkin SR; Jordan JT
    Neurology; 2023 Feb; 100(7):e661-e670. PubMed ID: 36332985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotype-phenotype correlation in neurofibromatosis type-1: NF1 whole gene deletions lead to high tumor-burden and increased tumor-growth.
    Well L; Döbel K; Kluwe L; Bannas P; Farschtschi S; Adam G; Mautner VF; Salamon J
    PLoS Genet; 2021 May; 17(5):e1009517. PubMed ID: 33951044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Size of tooth crowns and position of teeth concerning the extension of facial plexiform neurofibroma in patients with neurofibromatosis type 1.
    Friedrich RE; Giese M; Stelljes C; Froeder C; Scheuer HA
    Anticancer Res; 2012 May; 32(5):2207-14. PubMed ID: 22593511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells.
    Ferrer M; Gosline SJC; Stathis M; Zhang X; Guo X; Guha R; Ryman DA; Wallace MR; Kasch-Semenza L; Hao H; Ingersoll R; Mohr D; Thomas C; Verma S; Guinney J; Blakeley JO
    Sci Data; 2018 Jun; 5():180106. PubMed ID: 29893754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral Nerve Sheath Tumors in Patients With Neurofibromatosis Type 1: Morphological and Immunohistochemical Study.
    Friedrich RE; Nörnberg LKN; Hagel C
    Anticancer Res; 2022 Mar; 42(3):1247-1261. PubMed ID: 35220215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma.
    Tian Z; You Y; Xiao M; Liu J; Xu G; Ma C; Du Z; Wang Y
    Int J Med Sci; 2023; 20(1):125-135. PubMed ID: 36619222
    [No Abstract]   [Full Text] [Related]  

  • 20. Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas.
    Carrió M; Mazuelas H; Richaud-Patin Y; Gel B; Terribas E; Rosas I; Jimenez-Delgado S; Biayna J; Vendredy L; Blanco I; Castellanos E; Lázaro C; Raya Á; Serra E
    Stem Cell Reports; 2019 Feb; 12(2):411-426. PubMed ID: 30713041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.